RU2019121790A - Быстро распадающаяся фармацевтическая композиция - Google Patents
Быстро распадающаяся фармацевтическая композиция Download PDFInfo
- Publication number
- RU2019121790A RU2019121790A RU2019121790A RU2019121790A RU2019121790A RU 2019121790 A RU2019121790 A RU 2019121790A RU 2019121790 A RU2019121790 A RU 2019121790A RU 2019121790 A RU2019121790 A RU 2019121790A RU 2019121790 A RU2019121790 A RU 2019121790A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- hyaluronic acid
- matrix
- maltodextrin
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (23)
1. Фармацевтическая композиция, включающая открытую матричную ячеистую структуру, несущую один или несколько фармацевтически активных ингредиентов, где открытая матричная ячеистая структура включает мальтодекстрин и гиалуроновую кислоту или ее фармацевтически приемлемую соль.
2. Фармацевтическая композиция, включающая матрицу, несущую один или несколько фармацевтически активных ингредиентов, при этом матрица распадается при контакте с водной средой, указанная матрица включает мальтодекстрин и гиалуроновую кислоту или ее фармацевтически приемлемую соль.
3. Фармацевтическая композиция по п. 1 или 2, где гиалуроновая кислота имеет среднюю молекулярную массу в диапазоне от 1 × 104 до 1 × 107 дальтон, предпочтительно среднюю молекулярную массу 3 × 106±0,6 × 106 дальтон.
4. Фармацевтическая композиция по любому одному из пп. 1-3, имеющая предел прочности на разрыв по меньшей мере 0,1 Н/мм2.
5. Фармацевтическая композиция по любому одному из пп. 1-4, где мальтодекстрин и гиалуроновая кислота или ее фармацевтически приемлемая соль составляет от 10 до 99,99% от общей массы матрицы или открытой матричной ячеистой структуры и материала, переносимого матрицей или открытой матричной ячеистой структурой.
6. Фармацевтическая композиция по любому одному из пп. 1-5, где, в расчете на общую массу матрицы или открытой матричной ячеистой структуры и материала, переносимого матрицей или открытой матричной ячеистой структурой, мальтодекстрин составляет от 10 до 99% и гиалуроновая кислота или ее фармацевтически приемлемая соль составляет 0,99-5%, или мальтодекстрин составляет 40-99% и гиалуроновая кислота или ее фармацевтически приемлемая соль составляет 0,99-5%, или мальтодекстрин составляет 50-98% и гиалуроновая кислота или ее фармацевтически приемлемая соль составляет 0,99-3%.
7. Фармацевтическая композиция по любому одному из пп. 1-6, где композиция распадается в водной среде в течение 30 секунд.
8. Фармацевтическая композиция по п. 7, где композиция распадается в водной среде в течение 10 секунд.
9. Фармацевтическая композиция по любому одному из пп. 1-8, которая находится в лекарственной форме для перорального приема.
10. Фармацевтическая композиция по п. 9, которая адаптирована для сублингвального введения.
11. Фармацевтическая композиция по любому одному из пп. 1-10, где активный ингредиент представляет собой десмопрессин, десмопрессина ацетат, монтелукаст, монтелукаст натрия, силденафил, силденафила цитрат, силодозин или тадалафил.
12. Фармацевтическая композиция по любому одному из пп. 1-11, получаемая путем сублимации растворителя из отвержденного жидкого препарата, включающего активный ингредиент, мальтодекстрин и гиалуроновую кислоту или ее фармацевтически приемлемую соль в растворителе.
13. Способ получения фармацевтической композиции, включающий сублимацию растворителя из отвержденного жидкого препарата, включающего один или несколько фармацевтически активных ингредиентов, мальтодекстрин и гиалуроновую кислоту или ее фармацевтически приемлемую соль в растворителе.
14. Способ по п. 13, включающий: (a) введение единичных доз указанного жидкого препарата в углубления открытой блистерной упаковки; (b) отверждение жидкого препарата; и (c) сублимацию растворителя из отвержденного препарата с получением твердых единичных лекарственных форм в указанных углублениях.
15. Способ по п. 13 или 14, где растворитель представляет собой воду.
16. Способ по любому одному из пп. 13-15, где активный ингредиент представляет собой десмопрессин, десмопрессина ацетат, монтелукаст, монтелукаст натрия, силденафил, силденафила цитрат, силодозин или тадалафил.
17. Способ получения фармацевтической композиции, включающий:
(a) получение жидкого препарата, включающего мальтодекстрин, гиалуроновую кислоту или ее фармацевтически приемлемую соль и один или несколько активных ингредиентов, в растворителе;
(b) замораживание указанного жидкого препарата;
(c) сублимацию растворителя из замороженного препарата с получением фармацевтической композиции,
где фармацевтическая композиция распадается в течение 30 секунд при контакте с водной средой.
18. Способ по п. 17, который распадается в течение 10 секунд при контакте с водной средой.
19. Способ по п. 17 или 18, где композиция представляет собой композицию по любому одному из пп. 1-11.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201711001145 | 2017-01-11 | ||
IN201711001145 | 2017-01-11 | ||
PCT/EP2018/050635 WO2018130603A1 (en) | 2017-01-11 | 2018-01-11 | A fast disintegrating pharmaceutical composition |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019121790A true RU2019121790A (ru) | 2021-02-12 |
RU2019121790A3 RU2019121790A3 (ru) | 2021-02-15 |
RU2751193C2 RU2751193C2 (ru) | 2021-07-12 |
Family
ID=61054345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019121790A RU2751193C2 (ru) | 2017-01-11 | 2018-01-11 | Быстро распадающаяся фармацевтическая композиция |
Country Status (14)
Country | Link |
---|---|
US (1) | US10952959B2 (ru) |
EP (1) | EP3568124A1 (ru) |
JP (1) | JP7042275B2 (ru) |
KR (1) | KR20190104322A (ru) |
CN (1) | CN110049757A (ru) |
AU (1) | AU2018208531A1 (ru) |
BR (1) | BR112019010949A2 (ru) |
CA (1) | CA3046725A1 (ru) |
MX (1) | MX2019008288A (ru) |
MY (1) | MY195591A (ru) |
PH (1) | PH12019501260A1 (ru) |
RU (1) | RU2751193C2 (ru) |
WO (1) | WO2018130603A1 (ru) |
ZA (1) | ZA201904087B (ru) |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4780414A (en) | 1985-01-18 | 1988-10-25 | Bio-Technology General Corp. | Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus |
GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
US20080138399A1 (en) | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
US6761904B2 (en) | 2000-03-31 | 2004-07-13 | Nycomed Austria Gmbh | Pharmaceutical kit comprising midodrine as active drug substance |
WO2002002081A1 (en) | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
CA2417736A1 (en) | 2000-07-19 | 2002-01-24 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
US20030118653A1 (en) | 2001-07-06 | 2003-06-26 | Lavipharm Laboratories Inc. | Quick dissolving oral mucosal drug delivery device with moisture barrier coating |
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
PT1501534E (pt) | 2002-05-07 | 2006-09-29 | Ferring Bv | Formulacoes farmaceuticas |
US9561182B2 (en) | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US20040192582A1 (en) | 2002-12-19 | 2004-09-30 | Burnett Daniel R. | Ingestible formulations for transient, noninvasive reduction of gastric volume |
US8012505B2 (en) * | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
US20050074489A1 (en) | 2003-10-01 | 2005-04-07 | Pediamed Pharmaceuticals, Inc. | Effervescent and effervescent-dispersion compositions for medicaments and methods of use thereof |
CA2545194C (en) * | 2003-11-10 | 2014-10-21 | Seymour H. Fein | Pharmaceutical compositions including low dosages of desmopressin |
US20050136112A1 (en) | 2003-12-19 | 2005-06-23 | Pediamed Pharmaceuticals, Inc. | Oral medicament delivery system |
EP1763337A2 (en) | 2003-12-31 | 2007-03-21 | Actavis Group HF | Immediate, controlled and sustained release formulations of galanthamine |
EP1776089A2 (en) | 2003-12-31 | 2007-04-25 | Actavis Group hf | Donepezil formulations |
CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
US20060292099A1 (en) | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
EP1891937A1 (en) | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
BRPI0716270A2 (pt) * | 2006-08-28 | 2013-08-13 | Rexaderm Inc | bandagem de ferida seca e sistema de distribuiÇço de fÁrmaco |
WO2008065144A2 (en) | 2006-11-29 | 2008-06-05 | Novartis Ag | Galenic formulations of organic compounds |
US8900629B2 (en) | 2007-04-05 | 2014-12-02 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
KR100937625B1 (ko) | 2007-08-10 | 2010-01-20 | 주식회사 제닉 | 가용성 웹 공극필름 및 이의 제조방법 |
US20090047330A1 (en) | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Oral fast dissolving films for erectile dysfunction bioactive agents |
US20090047350A1 (en) | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Perforated water soluble polymer based edible films |
US20090060993A1 (en) | 2007-09-04 | 2009-03-05 | Joseph Schwarz | Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones |
KR20100094982A (ko) | 2007-11-13 | 2010-08-27 | 바이오-테크널러지 제너럴 (이스라엘) 리미티드 | 점탄성 바이오폴리머의 희석식 여과 멸균 방법 |
PE20091084A1 (es) | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
WO2010139654A2 (de) | 2009-06-04 | 2010-12-09 | Basf Se | Oral zerfallende dosierungsformen enthaltend geschmacksmaskierte wirkstoffe |
US8431122B2 (en) | 2009-07-02 | 2013-04-30 | Oxthera Intellectual Property Ab | Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
KR101138258B1 (ko) * | 2009-12-09 | 2012-04-24 | (주)바이오제닉스 | 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법 |
US10548839B2 (en) | 2010-03-16 | 2020-02-04 | Wei Tian | Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
RU2566269C2 (ru) | 2010-03-29 | 2015-10-20 | Ферринг Б.В. | Быстрорастворимая фармацевтическая композиция |
EP2399979B2 (en) | 2010-06-24 | 2021-12-29 | The Procter & Gamble Company | Soluble unit dose articles comprising a cationic polymer |
US20130039981A1 (en) | 2011-07-28 | 2013-02-14 | Subraman Rao Cherurkuri | Quick Dissolving, Long Acting Zinc Therapeutic Formulations |
JP6174585B2 (ja) | 2011-09-16 | 2017-08-02 | フェリング ベスローテン フェンノートシャップ | 速溶性医薬組成物 |
CN104125827A (zh) | 2011-10-12 | 2014-10-29 | 德拉沃有限责任公司 | 迅速口腔溶解的膳食补充剂 |
CN104023748B (zh) | 2011-10-28 | 2018-03-02 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
WO2013136346A2 (en) | 2012-03-15 | 2013-09-19 | Katakam Venkatesh | Taste masking pharmaceutical orally dissolving strips of lornoxicam |
US20140005304A1 (en) * | 2012-07-02 | 2014-01-02 | Baker Hughes Incorporated | Nanocomposite and method of making the same |
WO2014041489A2 (en) | 2012-09-11 | 2014-03-20 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
US8840425B2 (en) * | 2012-09-19 | 2014-09-23 | Yfc-Boneagle Electric Co., Ltd. | Connector apparatus and adapter apparatus with indication function |
CA2887893C (en) | 2012-10-09 | 2021-07-06 | Douglas SEARS | Therapeutic treatment for attention deficit disorder |
TW201422254A (zh) * | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
WO2014093850A1 (en) | 2012-12-13 | 2014-06-19 | Robert Davidson | Mouthguard for the delivery of active ingredients |
MX2013001278A (es) | 2013-01-31 | 2014-07-30 | Miguel Ángel García Pérez | Composicion farmaceutica con un sistema bifasico de liberacion inmediata para el control de eventos convulsivos y del dolor. |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
CN103211801B (zh) | 2013-04-02 | 2016-02-03 | 苏州人本药业有限公司 | 一种在口腔中快速溶解的膜剂及其制备方法 |
WO2014166994A1 (en) | 2013-04-09 | 2014-10-16 | Danmarks Tekniske Universitet | Nano-microdelivery systems for oral delivery of an active ingredient |
CN105682639B (zh) | 2013-07-31 | 2021-02-05 | 兰色制药医药工业股份有限公司 | 口腔可分散膜 |
EP2929885A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
CN104000800A (zh) | 2014-04-28 | 2014-08-27 | 万特制药(海南)有限公司 | 马来酸阿塞那平口腔速溶膜剂及其制备方法 |
WO2015169957A1 (en) | 2014-05-09 | 2015-11-12 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists |
KR101664106B1 (ko) | 2014-09-11 | 2016-10-10 | 한국화학연구원 | 폴리믹신 b 화합물을 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물 |
CN104523657A (zh) | 2014-12-26 | 2015-04-22 | 万特制药(海南)有限公司 | 苯磺酸氨氯地平口腔速溶膜及其制备方法 |
CN104958279A (zh) | 2015-06-27 | 2015-10-07 | 万特制药(海南)有限公司 | 氯雷他定口腔速溶膜及其制备方法 |
CN105663096B (zh) | 2016-01-25 | 2019-06-14 | 南京济群医药科技股份有限公司 | 一种沃诺拉赞口腔速溶膜剂及其制备方法 |
-
2018
- 2018-01-11 CN CN201880004920.7A patent/CN110049757A/zh active Pending
- 2018-01-11 WO PCT/EP2018/050635 patent/WO2018130603A1/en active Application Filing
- 2018-01-11 US US16/477,127 patent/US10952959B2/en active Active
- 2018-01-11 MY MYPI2019002844A patent/MY195591A/en unknown
- 2018-01-11 MX MX2019008288A patent/MX2019008288A/es unknown
- 2018-01-11 JP JP2019533200A patent/JP7042275B2/ja active Active
- 2018-01-11 EP EP18701677.9A patent/EP3568124A1/en not_active Withdrawn
- 2018-01-11 CA CA3046725A patent/CA3046725A1/en active Pending
- 2018-01-11 BR BR112019010949A patent/BR112019010949A2/pt not_active IP Right Cessation
- 2018-01-11 RU RU2019121790A patent/RU2751193C2/ru active
- 2018-01-11 AU AU2018208531A patent/AU2018208531A1/en not_active Abandoned
- 2018-01-11 KR KR1020197016752A patent/KR20190104322A/ko not_active Application Discontinuation
-
2019
- 2019-06-06 PH PH12019501260A patent/PH12019501260A1/en unknown
- 2019-06-24 ZA ZA2019/04087A patent/ZA201904087B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MY195591A (en) | 2023-02-02 |
MX2019008288A (es) | 2019-09-16 |
US10952959B2 (en) | 2021-03-23 |
WO2018130603A1 (en) | 2018-07-19 |
CN110049757A (zh) | 2019-07-23 |
US20190358156A1 (en) | 2019-11-28 |
AU2018208531A1 (en) | 2019-06-13 |
ZA201904087B (en) | 2022-01-26 |
PH12019501260A1 (en) | 2020-01-20 |
JP2020503305A (ja) | 2020-01-30 |
BR112019010949A2 (pt) | 2019-10-01 |
EP3568124A1 (en) | 2019-11-20 |
RU2019121790A3 (ru) | 2021-02-15 |
CA3046725A1 (en) | 2018-07-19 |
JP7042275B2 (ja) | 2022-03-25 |
RU2751193C2 (ru) | 2021-07-12 |
KR20190104322A (ko) | 2019-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012141140A (ru) | Быстрорастворимая фармацевтическая композиция | |
US9119794B2 (en) | Process to form a tablet and apparatus suitable for applying this process | |
JP6290346B2 (ja) | S1p調節剤を含む医薬組成物 | |
ES2558852T3 (es) | Proceso de formación de un comprimido y aparato adecuado para la aplicación de dicho proceso | |
KR100352881B1 (ko) | 소수성물질의제약학적인고체제형을제조하는방법 | |
JP2016175936A5 (ru) | ||
RU2012141141A (ru) | Быстрорастворимая фармацевтическая композиция | |
DK2698147T3 (en) | Oral film formulation with dapoxetine tadalafil | |
RU2004137118A (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления | |
RU2019144316A (ru) | Быстро распадающиеся вспененные пастилки с высокой массой в пересчете на единицу площади | |
RU2768868C2 (ru) | Соединения, предназначенные для лечения ожирения, и способы их применения | |
WO2017054772A1 (zh) | 一种使用滚模制备冻干赋形制剂的方法及其产品 | |
RU2018120693A (ru) | Мягкие желатиновые капсулы с рН-независимым высвобождением | |
RU2019121790A (ru) | Быстро распадающаяся фармацевтическая композиция | |
Malaak et al. | Orodispersible Tablets: Novel Strategies and future challenges in Drug Delivery | |
TW200526266A (en) | Non-tabletted, chewable, individually dosed administration forms | |
CA2900597C (en) | Chewable composition for oral administration and process for preparing thereof | |
CN110548011A (zh) | 包含s1p调节剂的药物组合物 | |
RU2019115816A (ru) | Фармацевтическая композиция | |
CN102349880B (zh) | 伊拉地平控释片及其制备方法 | |
ES2221840T3 (es) | Composicion o estructura microporosa expandida isotropa de disolucion rapida para uso farmaceutico, veterinario, dietetico, alimenticio o cosmetico y su procedimiento de obtencion. | |
Ravichandiran et al. | Fast dissolving tablets: A Review | |
RU2019119845A (ru) | Способ получения дозированной формы с покрытием | |
Patil et al. | Formulation and Evaluation of Mouth Dissolving Tablet | |
Sabry | Sodium cromoglycate mucoadhesive buccal patches: Design, fabrication, in vitro and in vivo characterization |